tiprankstipranks
The Fly

Bristol Myers announces EC approval of Breyanzi

Bristol Myers announces EC approval of Breyanzi

Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com